Anthrax vaccine absorbed
As of the edition of 20 October 2026, Anthrax vaccine absorbed is a vaccine component: marketed, first approved in 1998 (US); US protection ended in 2022.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1998
- Kind
- Vaccine component
- Brand name
- Biothrax
- First approved
- 12 November 1998 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Emergent Biosolutions
- Registered trials
- 6, 0 stopped early
- Disease areas
- Infections
US protection
US protection ended in 2022.
The orphan exclusivity ended in 2022 (it covers one use only). The application that gives this date is held by Emergent Biosolutions.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 6 |